




RealRate

PHARMACEUTICAL 2022

Deciphera Pharmaceuticals Inc.
Rank 370 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2022

Deciphera Pharmaceuticals Inc. Rank 370 of 475



The relative strengths and weaknesses of Deciphera Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Deciphera Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Deciphera Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is -318%, being 42% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	339,014
Cost of Goods Sold	2,932
Intangible Assets	0
Liabilities, Current	96,773
Liabilities, Non-Current	27,991
Other Assets	81,860
Other Compr. Net Income	40
Other Expenses	0
Other Liabilities	0
Other Net Income	113
Property and Equipment	8,610
Research and Development	257,040
Revenues	96,148
Selling, General and Administrative Expense	136,253

Output Variable	Value in 1000 USD
Assets	429,484
Liabilities	124,764
Expenses	396,225
Stockholders Equity	304,720
Net Income	-299,964
Comprehensive Net Income	-299,944
Economic Capital Ratio	-318%

